Home Contact Center Add this

Let's meet

ISSSI 2016

ISSSI 2016
August 30-02, 2016ALL EVENTS

13 July 2016 / International

Debiopharm acquires a majority holding in the Canadian start-up GenePOC [Read more]

11 July 2016 / international

Grand succès du Challenge Debiopharm Inartis [Read more]

07 June 2016 / international

Debiopharm International SA initiates clinical phase II study evaluating Debio 1143 in Ovarian Cancer [Read more]


13 July 2016

Debiopharm acquires a majority holding in the Canadian start-up GenePOC [Read more]

02 June 2016

FDA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of ovarian cancer [Read more]

15 April 2016

Debiopharm International SA announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor [Read more]


18 December 2014

Debiopharm Investment, Ardian, Nixdorf Foundation and Bernis today acquire Eco Delta solar activities [Read more]

27 November 2014

Debiopharm Investment becomes a minority shareholder in Haut-Lac International Bilingual School in St-Légier (VD) [Read more]

17 November 2014

Coorpacademy, établi à l’EPFL et l’un des leaders des MOOCs à destination des entreprises, lève 3,2 millions d’euros auprès de Debiopharm Investment et du fonds français NextStage [Read more]


21 June 2016

Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients [Read more]

30 April 2016

Phase 1 Study of Debio 1143 with Concurrent Chemo-Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Y. [Read more]

21 April 2016

FGFR selective inhibitor Debio1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models [Read more]


bulle slideshow group

bulle slideshow diagnostics

bulle slideshow international

bulle slideshow investment

bulle slideshow research